Oncosil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more
Oncosil Medical Ltd (OSL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -1.814x
Based on the latest financial reports, Oncosil Medical Ltd (OSL) has a cash flow conversion efficiency ratio of -1.814x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-6.96 Million) by net assets (AU$3.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncosil Medical Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Oncosil Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncosil Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncosil Medical Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Obase Bilgisayar ve Danismanlik Hizmetleri Ticaret A.S.
IS:OBASE
|
0.116x |
|
Huntwicke Capital Group Inc
PINK:HCGI
|
-0.058x |
|
INC S.A.
WAR:INC
|
-0.047x |
|
Carlton Precious Inc.
V:CPI
|
N/A |
|
PEZM Gold Inc
V:PEZM-H
|
-0.022x |
|
Placoplatre SA
PA:MLPLC
|
N/A |
|
Chukai Public Company Limited
BK:CRANE
|
0.026x |
|
Ambipar Emergency Response
NYSE MKT:AMBI
|
0.074x |
Annual Cash Flow Conversion Efficiency for Oncosil Medical Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Oncosil Medical Ltd from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$3.10 Million | AU$-12.06 Million | -3.887x | -70.07% |
| 2024-06-30 | AU$4.74 Million | AU$-10.82 Million | -2.285x | -99.55% |
| 2023-06-30 | AU$9.88 Million | AU$-11.32 Million | -1.145x | -26.45% |
| 2022-06-30 | AU$11.16 Million | AU$-10.11 Million | -0.906x | -20.17% |
| 2021-06-30 | AU$11.70 Million | AU$-8.82 Million | -0.754x | -270.43% |
| 2020-06-30 | AU$21.90 Million | AU$-4.46 Million | -0.203x | +71.04% |
| 2019-06-30 | AU$10.68 Million | AU$-7.50 Million | -0.703x | -51.92% |
| 2018-06-30 | AU$18.15 Million | AU$-8.40 Million | -0.463x | +23.27% |
| 2017-06-30 | AU$10.13 Million | AU$-6.11 Million | -0.603x | -95.27% |
| 2016-06-30 | AU$14.81 Million | AU$-4.57 Million | -0.309x | -1155.70% |
| 2015-06-30 | AU$6.96 Million | AU$-171.16K | -0.025x | +96.33% |
| 2014-06-30 | AU$9.52 Million | AU$-6.37 Million | -0.669x | -758.32% |
| 2013-06-30 | AU$6.05 Million | AU$-471.91K | -0.078x | +36.67% |
| 2012-06-30 | AU$2.48 Million | AU$-305.78K | -0.123x | -13.30% |
| 2011-06-30 | AU$2.91 Million | AU$-316.67K | -0.109x | -281.54% |
| 2010-06-30 | AU$2.58 Million | AU$154.35K | 0.060x | +346.60% |
| 2009-06-30 | AU$4.28 Million | AU$-103.97K | -0.024x | +95.45% |
| 2008-06-30 | AU$4.09 Million | AU$-2.18 Million | -0.533x | -85.54% |
| 2007-06-30 | AU$4.68 Million | AU$-1.35 Million | -0.288x | -902.55% |
| 2006-06-30 | AU$5.46 Million | AU$195.51K | 0.036x | +278.21% |
| 2005-06-30 | AU$899.56K | AU$-18.08K | -0.020x | -- |